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AbstrAct
Objective To describe and classify health technologies 
predicted in forecasting studies.
Design and methods A portrait describing health 
technologies predicted in 15 forecasting studies published 
between 1986 and 2010 that were identified in a previous 
systematic review. Health technologies are classified 
according to their type, purpose and clinical use; relating 
these to the original purpose and timing of the forecasting 
studies.
Data sources All health-related technologies predicted in 
15 forecasting studies identified in a previously published 
systematic review.
Main outcome measure Outcomes related to (1) each 
forecasting study including country, year, intention 
and forecasting methods used and (2) the predicted 
technologies including technology type, purpose, targeted 
clinical area and forecast timeframe.
results Of the 896 identified health-related technologies, 
685 (76.5%) were health technologies with an explicit or 
implied health application and included in our study. Of 
these, 19.1% were diagnostic or imaging tests, 14.3% 
devices or biomaterials, 12.6% information technology 
systems, eHealth or mHealth and 12% drugs. The majority 
of the technologies were intended to treat or manage 
disease (38.1%) or diagnose or monitor disease (26.1%). 
The most frequent targeted clinical areas were infectious 
diseases followed by cancer, circulatory and nervous 
system disorders. The most frequent technology types 
were for: infectious diseases—prophylactic vaccines 
(45.8%), cancer—drugs (40%), circulatory disease—
devices and biomaterials (26.3%), and diseases of the 
nervous system—equally devices and biomaterials 
(25%) and regenerative medicine (25%). The mean 
timeframe for forecasting was 11.6 years (range 0–33 
years, median=10, SD=6.6). The forecasting timeframe 
significantly differed by technology type (p=0.002), the 
intent of the forecasting group (p<0.001) and the methods 
used (p<001).
conclusion While description and classification 
of predicted health-related technologies is crucial 
in preparing healthcare systems for adopting new 
innovations, further work is needed to test the accuracy of 
predictions made.
IntrODuctIOn
People are in general living longer and 
surviving previously life-threatening illnesses. 
A proportion of this effect is attributed to the 
use of novel health interventions and tech-
nologies, such as new vaccines to prevent 
disease; new diagnostic tests to diagnose 
diseases earlier and with improved accuracy 
and new drugs, devices and surgical proce-
dures to treat diseases more effectively. In 
addition, new health technologies may also 
be used to enhance function and improve 
quality of life, such as prostheses, sensory 
aids and cosmetic enhancements. Techno-
logical advances and innovation are leading 
to new health interventions becoming avail-
able to healthcare markets at an increasing 
speed; these often cost more than current 
alternatives and significantly affect the cost of 
healthcare services and delivery.1 2 To ensure 
that patients can access the most effective and 
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strengths and limitations of the study
 ► The study is a comprehensive description and 
classification of health-related technologies 
predicted in 15 forecasting studies identified in a 
previously published systematic review.
 ► The study summarises the forecast technologies 
by type, for example, medical devices, diagnostic 
tests or drugs; by clinical purpose, for example, 
prevention, diagnosis or treatment and by targeted 
clinical area by International Classification of 
Diseases, 10th revision chapter and relates this to 
the forecasting purpose and timeframe.
 ► The analysis and the health-related technologies 
identified are constrained by the methods used in 
the forecasting studies, for example, by the areas of 
interest of the experts involved.
 ► Although the study highlights the identified 
technologies, the retrospective accuracy of the 
studies remains to be researched.
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Table 1 Fifteen forecasting studies identified in the prior systematic review
Study name or first author Year of forecast Country
Dutch Steering Committee on Future Health Scenarios (STG), 1988 1986 The Netherlands
Spiby, 1988 1988 UK
Loveridge et al6 1994 UK
Stevens et al7 1995 UK
Karim, National Research and Technology Foresight Project, 1999 1996 South Africa
Operating theatre of the year, 2010; Department of Trade and Industry 
report, 1999
1996 UK
Cahill and Scapolo18 1998 Europe
Daar et al 2002 Developing countries
Technology foresight towards 2020_China 2003 China
British Telecommunications (BT) calendar 1997 & 2005 UK
Tremblay and Yiu 2006 Canada
Food and Drug Administration surveys 1998 and 2008 USA
Institute of the Future, 2009 2009 USA
Science & Technology Foresight Survey, 2010 Every 5 years from 1971, 
latest survey 2009–2010
Japan
UK technology and innovation futures for the 2020s, 2010 2010 UK
Source:  Doos et al.9
cost-effective interventions, and because many health 
systems work within constrained budgets, healthcare 
systems need to be prepared to respond to new develop-
ments. A crucial step in such preparation is the accurate 
identification and forecasting of likely significant techno-
logical healthcare developments.3 4
Forecasting is widely used for planning and strategic 
decision-making around industrial and economic devel-
opment at organisational, regional and national levels.5 
Within healthcare, forecasting can be used to build strate-
gies for supporting innovators and companies to develop 
new interventions, to plan future research programmes 
and delivery of healthcare and to prepare health services 
and personnel to respond to technological develop-
ments of benefit to patients and service provision. Health 
technology forecasting uses various methods, such as 
Delphi surveys and reviews of the literature6–8 to iden-
tify emerging health technologies that are intended 
to address important unmet healthcare needs or that 
need additional evaluation and to analyse their potential 
impact on patients and health systems.4
To get the maximum benefit from forecasting, it is 
important that the methods used to identify emerging 
interventions and technologies are appropriate for the 
aims and timeframe of the forecasting exercise and also 
as accurate as possible.
In a recent systematic review,9 we found 15 forecasting 
studies with 3 to 20 year timeframes that identified 
emerging health-related topics and technologies predicted 
between 1986 and 2010 from 12 high-income countries, 
including 6 from the UK. Identifying and classifying the 
predicted new technologies into meaningful groupings is 
important for healthcare system preparedness, allowing 
planned assessment and adoption as appropriate. Here 
we describe and classify the health technologies predicted 
in the forecasting studies according to their type, purpose 
and clinical use. We relate these to the forecast time 
period and develop an overview of the technological and 
clinical frontiers of innovation in health and healthcare 
provision.
MethODs
See table 1 for a full list of the 15 studies identified in our 
prior systematic review. We extracted all forecast topics 
from the 15 forecasting studies using a standardised set of 
data for each of these predicted topics and on the source 
study. Data related to the forecast topics included the 
name of the topic as written in the forecasting reports 
and papers, and the predicted forecast timeframe. Data 
related to the study included the country or region of the 
forecast, year the study was undertaken, its intention and 
remit, the study forecasting timeframe and the number 
and type of forecasting methods used.
Identification and inclusion of health technologies
For final inclusion and analysis, topics had to be health 
technologies as defined by the National Institute of Health 
Research (NIHR) Health Technology Assessment (HTA) 
programme10: ‘any method used to promote health; 
prevent and treat disease; and improve rehabilitation or 
long-term care. They are not confined to new drugs and 
include any intervention used in the treatment, preven-
tion or diagnosis of disease’. We also included topics that 
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related to the recognition of, or change in, health states or 
emotions, or health-related behaviours. All topics needed 
to have an explicit or implied health-related application 
or identified patient group for final inclusion. Topics 
were excluded if they related exclusively to foods, plants, 
animals, insects, new sources of fuel or energy, environ-
mental contamination, legislation or health insurance.
LD read all the included studies and manually extracted 
all technologies mentioned in the forecast from the 
published text and related tables. Two authors (CP and 
LD) independently scrutinised each identified topic and 
applied the inclusion and exclusion criteria. Where there 
was insufficient information on a topic to make the inclu-
sion/exclusion decision, we undertook brief and very 
limited searches on the internet to find additional infor-
mation.
All topics classed as a health technology with an explicit 
or implied health-related application were subsequently 
coded based on their technology type, intended purpose 
and targeted clinical use.
Technology type
we used broad categories: assistive devices and rehabili-
tation aids, devices and biomaterials, diagnostic tests and 
imaging, drugs, information technology (IT) systems, 
electronic health systems (eHealth) and mobile health 
(mHealth), medical equipment, non-surgical therapy, 
organisational programmes, prophylactic vaccines, popu-
lation programmes, regenerative medicine approaches 
and therapeutic procedures.
Technology purpose
we used categories that relate to the intended point on the 
patient pathway: health promotion and the prevention of 
disease, diagnosis and monitoring of disease, treatment 
and management of symptoms and disease, and rehabil-
itation. We supplemented these with two groupings that 
categorised technologies that support the provision of 
care (1) supporting patients receiving care and designed 
to be used by individuals (patients, caregivers or health-
care professionals) and (2) supporting the provision of 
care and/or increasing service efficiency.
Targeted clinical area (specialty)
we used the international statistical classification of 
diseases and related health problems 10th revision 
(ICD-10)11 chapter headings relating to diseases and 
other morbid conditions (chapters I–XVII); symptoms, 
signs and abnormal findings (chapter XVIII); injuries, 
poisoning and other consequences of external causes 
(chapter XIX); external causes of diseases and morbid 
conditions chapter XX) and factors influencing health 
status and contact with health services for people not 
currently sick (chapter XXI). Chapter XXI includes 
contraception, technologies used in population 
screening, health promotion and disease prevention, and 
general rehabilitation.
All topics with disputed inclusion, exclusion or cate-
gorisation were initially discussed between two authors 
(LD and CP) and disagreements resolved where possible. 
Where disagreements remained, topics were discussed 
with the other authors as a group and the final categorisa-
tion agreed through consensus.
Technology forecast timeframe
For each health-related technology forecast, we calcu-
lated the difference in years between each technology’s 
predicted year of impact as identified in the original 
study, and the year when the prediction was made, that 
is, the year of the original study. Technology forecasts 
were classified as short term if their forecasting time-
frame was less than 3 years, short to medium term if it 
was 3–10 years, medium to long term if it was 11–20 years 
and long term for those with timeframes of more than 20 
years. Although the original systematic review excluded 
forecasting studies which exclusively adopted a short 
timeframe of less than 3 years, some studies with longer 
timeframes also provided predictions with shorter time-
frames, and these were included in the analysis.
Data analysis
We analysed the data using IBM SPSS statistics (V.22) for 
Windows. We present descriptive analyses as means and 
SD for normally distributed continuous variables. Statis-
tically significant differences were determined using 
ANOVA for continuous normally distributed data and X2 
for dichotomous variables.
results
We identified 896 predicted topics from the 15 fore-
casting studies. Of these, we judged that 685 (76.5%) 
were health-related technologies with an explicit or 
implied health-related application. The most frequently 
excluded topics were those that described advances in 
the underpinning scientific knowledge (8.7%), such 
as determination of whole human DNA base sequence 
and identifying genetic links to diseases. A full list of the 
included health-related technologies is attached as an 
online supplementary appendix 1.
Of the 685 health-related technologies, 52.3% were 
forecast from six studies by governmental organisations 
(such as the UK Department of Trade and Industry12), 
21.9% by commercial/consultancy organisations (such as 
British Telecommunications), 14.5% by policy planning 
groups (such as Loveridge et al,6 8.9% by research groups 
(such as those by Stevens et al7 and 2.5% by non-profit 
organisations (such as Institute of the Future13). Looking 
at the purpose of forecasting, our data showed that 
two-thirds (68%) of the health technologies were fore-
cast for policy planning purposes, 18.1% for research 
purposes and 13.9% for commercial purposes.
Nearly half (48.9%) of the identified technologies 
were from six UK-based studies and reports, 15% were 
from Japan, 11.7% from the Netherlands, 11.4% from 
the USA and 8% from Canada. The remainder were from 
a homogenous group of developing countries and South 
Africa (3.8%), other European countries (0.9%) and 
China (0.3%).
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Table 2 Health technologies by technology type
Technology type n %
Diagnostic tests and imaging 131 19.1
Devices and biomaterials 98 14.3
IT systems, eHealth and mHealth 86 12.6
Drugs (not prophylactic vaccines) 82 12.0
Regenerative medicine 80 11.7
Medical equipment 37 5.4
Therapeutic procedures 36 5.3
Unknown 33 4.8
Organisational programmes 26 3.8
Prophylactic vaccines 24 3.5
Population programmes 24 3.5
Non-surgical therapy 15 2.2
Other 9 1.3
Assistive devices 4 0.6
Total 685 100
IT, information technology; eHealth, electronic health; mHealth, 
mobile health.
technology type
Of the 685 health technologies forecast, 19.1% were diag-
nostic tests and imaging technologies, such as advanced 
ultrasound imaging systems and molecular diagnosis; 
14.3% were devices and biomaterials, such as tissue engi-
neered devices and drug impregnated devices; 12.6% 
were IT systems, eHealth and mHealth, such as electronic 
prescriptions and telemedicine; 12% were drugs, such 
as new anaesthetic vapours and electronically activated 
drugs and 11.7% were regenerative medicine approaches, 
such as gene therapy for diabetes and widespread use of 
gene therapy for familial hypercholesterolaemia (table 2 
and online supplementary appendix 1). Drug technol-
ogies were more commonly forecast in studies carried 
out by researchers (36.1%) than other groups, while 
technologies for diagnostic tests and imaging were more 
commonly forecast in studies by governmental agencies 
than other groups (table 3). Regenerative medicine 
approaches were the most commonly forecast technolo-
gies (23.2%) by studies with a commercial intent while 
diagnostic tests and imaging were the most commonly 
forecast technologies by studies with policy planning 
and research intentions (20.6% and 23.4%, respectively) 
(p<0.001).
technology purpose
Of the 685 health technologies included in the forecasting 
reports, 38.1% were for the treatment and management 
of symptoms and disease, such as development of effec-
tive treatment for amyotrophic lateral sclerosis and the 
practical use of gene therapy for genetic disorders; 21.6% 
for the diagnosis and monitoring of disease, for example, 
a diagnostic biochip for cancer and the further develop-
ment of three-dimensional imaging techniques; 13% for 
health promotion and the prevention of disease, such as 
the first effective vaccine of HIV and DNA vaccines for 
AIDS, malaria, hepatitis B and certain cancers; 10.2% for 
supporting the provision of care, for example, telemoni-
toring and teleconsultation; 8% for supporting patients 
receiving care, such as smart pill bottles to remotely 
monitor medication use and thought-controlled robots 
for personal healthcare; and 4.7% for rehabilitation, for 
example, artificial legs and robotic prosthetics.
Technologies for treatment and disease management 
were the most common regardless of the intention of the 
study: 35.8% among studies with a commercial intent, 
35.8% for policy planning and 48.4% for research. Tech-
nologies for treatment and disease management were 
also the most common technologies forecast by all the 
various groups (60.7% among researchers, 39.9% among 
governmental organisations and 35.8% among commer-
cial organisations).
targeted clinical area
Using the ICD-10 codes to define the targeted clinical 
area, just over half of the health technologies (50.4%) 
were for diseases and conditions that were not specified or 
that could not be coded or that crossed multiple special-
ities. Of the 340 health technologies that could be coded 
to a specific ICD-10 chapter, the top five targeted clin-
ical areas were the following: (1) infectious and parasitic 
diseases ICD-I (14.1%), such as development of vaccines 
for AIDS and vaccines for malaria, (2) neoplasms ICD-II 
(11.8%), such as expanding metal stents for oesophageal 
cancer and diagnostic biochip for cancer, (3) diseases of 
the circulatory system ICD-IX (11.2%), such as artificial 
muscles in replace of heart transplants and implantable 
vascular stents, (4) diseases of the nervous system ICD-VI 
(10.6%), such as artificial brain cells and artificial periph-
eral nerves and (5) factors influencing health status and 
contact with health services ICD-XXI (10.3%), such as 
a personal wearable health monitor and extension of 
average lifespan to over 100.
Congenital malformations, deformations and chromo-
somal abnormalities ICD-XVII and symptoms, signs and 
abnormal clinical and laboratory findings, not elsewhere 
classified ICD-XVIII had the fewest forecast technologies 
(0.3% each).
Table 4 shows the technology types and purposes for 
the forecast technologies within the five most frequent 
targeted clinical areas. The most frequent technology type 
forecast for infectious and parasitic diseases were prophy-
lactic vaccines (45.8%); for cancer were drugs (40%); 
for diseases of the circulatory system were devices and 
biomaterials (26.3%); for diseases of the nervous system 
were devices and biomaterials (25%) and regenerative 
medicine (25%) and for factors influencing health status 
and contact with health services including screening and 
rehabilitation, devices and biomaterials (31.4%). The 
most frequent technology purpose was health promotion 
and disease prevention for both infectious and parasitic 
diseases (ICD-I) (60.4%) and factors influencing health 
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Table 5 Mean technology prediction timeframe (years) by 
technology type*
Technology type n
Mean 
timeframe,
years (SD)
Non-surgical therapy 14 9.07 (5.7)
Diagnostic tests and imaging 113 10.11 (6.0)
Drugs (not prophylactic vaccines) 75 10.31 (6.3)
Therapeutic procedures 31 10.45 (8.2)
Organisational programmes 25 10.48 (5.3)
IT systems, eHealth and mHealth 77 11.08 (5.5)
Devices and biomaterials 88 11.93 (6.8)
Assistive devices 3 12.33 (17.9)
Other/unknown 40 13.35 (7.2)
Medical equipment 36 13.53 (2.7)
Regenerative medicine 73 13.58 (7.4)
Prophylactic vaccines 13 14.00 (6.3)
Population programmes 19 14.53 (5.9)
Total 607 11.59 (6.6)
*p<0.002.
IT, information technology; eHealth, electronic health; mHealth, 
mobile health.
Figure 1 Mean forecast timeframe by methods of forecasting.*p<0.001
status and contact with health services including screening 
and rehabilitation (ICD-XXI) (51.4%). Technologies for 
treatment and disease management were most common 
for cancer (55.0%), diseases of the circulatory system 
(65.8%) and nervous system disorders (61.1%).
technology forecast timeframe
Data were available to calculate the prediction time-
frame for 607 of the identified health technologies. The 
mean timeframe for forecasting predictions was 11.6 
years (range 0–33 years, median=10, SD=6.6). There 
was a significant difference in the mean prediction time-
frame by technology type (p=0.002), with non-surgical 
therapies having the shortest mean forecast timeframe 
(9.07 years) and population health programmes having 
the longest mean forecast (14.53 years) (table 5). There 
were no statistically significant differences in the mean 
duration of the technology prediction timeframe by the 
technology purpose and we were not able to detect any 
particular trend in the technology types or purposes of 
forecast overtime.
There was a statistically significant difference in the 
forecast timeframe by the type of group undertaking the 
forecasting (p<0.001): 58% of the long-term forecasts 
(>20 years) were made by policy planning groups and 
51% of short-term forecasts (<3 years) were by research 
groups.
Technologies forecast by studies with research inten-
tions had the shortest mean forecast timeframe (4.49 
years) while those for policy-making had the longest time-
frame (14.16 years) (p<0.001). Similarly, technologies 
forecast by researchers had significantly shorter mean 
timeframes (3.56 years) compared with those made by 
governmental agencies which had the longest mean fore-
cast timeframes (13.42 years) (p<0.001).
There was a statistically significant difference in the 
mean forecast timeframe when considering the fore-
casting method (p<0.001) (figure 1). Technologies 
forecast using methods that included creativity-based 
methods which require brainstorming, such as scenario 
building, had a significantly longer forecasting timeframe 
(13.5 years) compared with those did not include creativ-
ity-based methods such as literature reviews (9.7 years) 
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(p<0.001). On the other hand technologies forecast 
using methods that included evidence-based methods 
such as literature reviews and evidence from HTA organ-
isations, had significantly shorter forecasting timeframes 
(8.2 years) than those that did not include evidence-based 
methods (10.8 years) (p<0.001).
DIscussIOn
Being aware of forthcoming developments in healthcare 
and preparing for the future is desirable for health policy 
makers, whether developing healthcare policy, directing 
future research or commissioning health services. The use 
that health policy makers make of forecasting depends on 
having systems in place that receive and act on the infor-
mation at an appropriate time. There are few examples 
of such systems in the published literature14; however, 
the relationship between the UK’s National Institute for 
Health and Care Excellence and NIHR Horizon Scanning 
Research and Intelligence Centre does provide a model 
of how shorter-term early awareness intelligence can 
shape prioritisation decisions.15 We found that more than 
two-thirds of the identified technologies were forecast 
for policy planning purposes and over half were forecast 
by governmental organisations, and that the majority of 
long-term forecasts were made by policy planning groups 
as opposed to research groups. This finding supports the 
premise that the majority of forecasting is carried out for 
service preparedness and long-term planning and stra-
tegic decision-making.5
Our study identified and classified a number of 
important health-related technologies, which health 
services may have already had to manage or will have to 
do so in the future. Our finding that nearly 60% of the 
technologies were either for the treatment and manage-
ment of symptoms and disease or for the diagnosis and 
monitoring of disease can perhaps be explained by the 
methods used for forecasting. Many of the studies involved 
soliciting the opinion of experts and, although it is not 
possible to be certain about the areas of interest of those 
involved, their expertise may have made them more likely 
to focus on diagnosis and treatment than, for example, 
organisational programmes or rehabilitation. Regen-
erative medicine approaches were the most commonly 
forecast technologies by studies with a commercial intent. 
In contrast, drugs and related technologies (but not 
prophylactic vaccines) were the most common forecasts 
made by researchers.
The four clinical areas with the greatest number of 
forecast health technologies: infectious diseases, cancer, 
circulatory and nervous system diseases and disorders, 
include many of the major causes of death and disability 
in countries today. Again we are not able to deter-
mine if this merely reflects the interests of the groups 
carrying out the forecasting and their areas of expertise 
or whether it truly represents the technology innova-
tion frontier. It is understandable that the forecasts for 
infectious disease included many prophylactic vaccines 
as these have proven to be a cost-effective preventive 
strategy for their prevention.16 This was also supported 
by our finding that forecasts of vaccine related technol-
ogies were only made by governmental agencies and 
policy research groups. In cancer, forecasting included 
both drugs and diagnostic tests and imaging, perhaps 
reflecting increasing targeting in novel cancer ther-
apies.17 18 Several forecasts of regenerative medicine 
approaches for nervous system diseases and disorders 
is also interesting, with many of these diseases not 
currently curable or effectively treated.19 20
Our finding that forecasts which included creativ-
ity-based methods, such as scenario building and 
analysis had, on the whole, longer forecast timeframes 
than studies that included evidence-based methods may 
have a rationale. Evidence-based methods require there 
to be research evidence on technologies, which will 
therefore probably be nearer to any predicted impact. In 
contrast, creativity-based methods require experts to think 
more widely about what the future could be and are not 
therefore constrained by what is actually being currently 
researched and published. This may also explain our 
finding that just over half of the short-term forecasts were 
made by research groups who may be more likely to use 
published evidence to inform their deliberations.
We believe that this is the first study to comprehen-
sively identify and summarise health-related technologies 
predicted in past forecasting projects and to categorise 
and describe them. Although as many predicted topics 
as possible were included, we did exclude a substantial 
number. This was often because we could not envisage 
a future health application or because there was insuffi-
cient information to make a judgement (and many topics 
had very sparse titles or descriptive information). By 
excluding topics in this way, we may have excluded some 
that would have had an explicit health application within 
a reasonable timeframe. In addition, it is likely that we 
were unable to identify a number of relevant forecasts 
made by commercial organisations, which will have been 
conducted and disseminated in confidence.
Our description and classification of predicted 
health-related technologies from prior forecasting studies 
provides an overview of the technological and clinical 
frontiers of innovation in health and healthcare provision. 
To complete our evaluation of the accuracy of previous 
forecasting predictions and the forecasting methods 
used, the accuracy of the predictions made should also be 
assessed. This may be difficult across all technology types 
and clinical areas, but possible by limiting the evaluation 
to specific clinical areas and/or technology types or to 
those topics with more obvious health applications and 
timeframes that have already occurred.
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